ARTICLE | Clinical News
Avicine: Started Phase III trial
January 8, 2001 8:00 AM UTC
AVI BioPharma Inc. (AVII), Portland, Ore. Product: Avicine Business: Cancer Therapeutic category: Immune stimulation Target: Immune cells Description: Synthetic peptide vaccine against human chorioni...